TRINETRA › Sectors › Healthcare
Dr. Lal Path Labs Ltd. (LALPATHLAB) — share price, P/E and fundamentals
Dr. Lal Path Labs Ltd. (NSE: LALPATHLAB) closed at ₹1,907.20 on 30 Oct 2026, +22.7% over one year, against a 52-week range of ₹1,272.60 – ₹2,038.60.
In the quarter ended 30 Jun 2026 (consolidated, filed 24 Jul 2026) it reported revenue of ₹798 cr and net profit of ₹170 cr, a 21.3% net margin; revenue grew 19.1% and profit grew 26.3% year on year.
On four consecutive filed quarters its trailing P/E is 59.0; since 25 Apr 2025 its own P/E has ranged from 41.3 to 61.8 (median 52.8), and today's reading is higher than 90% of those 374 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 27.0%, ROCE 34.9%, debt-to-equity 0.00, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 79% of 63 sector peers; PBT margin higher than 82% of 63 sector peers; ROE higher than 92% of 63 sector peers.
Key figures
| Last close | ₹1,907.20 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -2.8% / +35.4% / +22.7% |
| 52-week low – high | ₹1,272.60 – ₹2,038.60 |
| Market capitalisation | ₹31,965 cr |
| Trailing P/E | 59.0 |
| Price / book | 12.74 |
| EV / EBITDA | 34.8 |
| Earnings yield | 1.7% |
| TTM EPS | ₹32.33 |
| TTM net profit | ₹542 cr |
| Quarter revenue | ₹798 cr |
| Quarter net profit | ₹170 cr |
| Net margin | 21.3% |
| Revenue growth (YoY) | +19.1% |
| Profit growth (YoY) | +26.3% |
| Return on equity | 27.0% |
| ROCE | 34.9% |
| Debt / equity | 0.00 |
| Current ratio | 3.48 |
| Free cash flow | ₹469 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹42.0 cr |
Against Healthcare peers
| Metric | LALPATHLAB | Peer median | Percentile |
|---|---|---|---|
| Net margin | 21.25 | 12.67 | 79 |
| PBT margin | 28.67 | 17.57 | 83 |
| ROE | 27.03 | 13.86 | 92 |
| ROCE | 34.88 | 16.59 | 94 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 1.25 | 1.25 | 50 |
| Trailing P/E | 58.99 | 43.07 | 70 |
| P/B | 12.74 | 5.88 | 82 |
Questions
What is the P/E ratio of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd.'s trailing P/E is 59.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 25 Apr 2025 its P/E has ranged 41.3–61.8.
What were Dr. Lal Path Labs Ltd.'s latest quarterly results?
For the quarter ended 30 Jun 2026, Dr. Lal Path Labs Ltd. reported revenue of ₹798 cr and net profit of ₹170 cr (consolidated), filed with the exchange on 24 Jul 2026.
What is Dr. Lal Path Labs Ltd.'s ROE?
Return on equity is 27.0% based on the balance sheet dated 31 Mar 2026.
Does Dr. Lal Path Labs Ltd. have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is LALPATHLAB's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, LALPATHLAB traded between ₹1,272.60 and ₹2,038.60.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.